GoKawiilUS Cancer Patients Turn to Shanghai for Cheaper CAR-T Immunotherapy
American cancer patients are increasingly traveling to China for CAR-T cell therapy, a personalized immunotherapy that reengineers a patient's white blood cells to fight cancer. The Wall Street Journal reports that Chinese providers, having scaled up production, now offer the treatment for $150,000 to $230,000 versus $550,000 to $850,000 in the US, with faster turnaround and included follow-up care.
GoKawiil's interpretation of the reporting above, not reported fact.
The trend reveals how US drug pricing and supply bottlenecks are pushing even life-saving, cutting-edge treatments developed domestically out of reach for many Americans. China's ability to mass-produce and lower costs for a therapy invented in the US signals a shifting balance in biotech manufacturing and could pressure US providers and regulators to address affordability and access gaps.
- CAR-T therapy in China costs roughly one-third of the US price for the same treatment.
- US oncologists are now referring patients abroad due to domestic cost and supply shortages.
- China's industrialization of CAR-T production challenges US dominance in advanced biotech treatments.
Source: futurism.com — Joe Wilkins, 2026-09-13
Published there as: “America’s Health Care System Is So Screwed That Patients Are Flying to China for Cancer Treatment”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.